#United Kingdom #Bio-Techne #Bristol #Cell Therapy #GMP Manufacturing

Bio-Techne Expands GMP Manufacturing Network: New Facility in Bristol

Bio-Techne Corporation, a prominent player in the life sciences sector, has officially launched a new manufacturing facility dedicated to Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom. This strategic move is aimed at bolstering the company's global footprint and addressing the burgeoning demand within the cell therapy market. The facility, spanning 10,000 square feet, boasts five ISO-8 multifunctional cleanrooms along with two ISO-7 cleanrooms tailored for GMP small molecule production. This state-of-the-art setup has been crafted to meet the stringent requirements of advanced cell therapy manufacturing, ensuring that customers receive high-quality GMP materials underpinned by robust quality management systems.

CEO Kim Kelderman emphasized the importance of this expansion, stating, "As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale." The Bristol facility illustrates Bio-Techne's resolve to equip customers with the necessary resources and expertise to help bring transformative therapies to market efficiently and reliably.

In addition, this development is part of Bio-Techne's comprehensive strategy to create a robust manufacturing network that caters to cell therapy workflows from inception through to commercial production. The company's interconnected operations span across Minneapolis, Minnesota, and St. Paul, alongside strategic collaborations with key industry partners like Wilson Wolf Corporation, known for its innovative G-Rex® platform used in cell culture. Together, they provide an integrated portfolio of services that simplifies the transition for clients from research phases to clinical development and eventual market release.

A pressing concern for cell therapy developers lies in the demand for standardized manufacturing processes that can efficiently scale production while adhering to evolving regulatory frameworks. Bio-Techne tackles these challenges by delivering top-notch GMP materials, innovative manufacturing solutions, and analytical technologies specifically engineered to enhance consistency and expedite development timelines. Industry discussions have increasingly pinpointed scalability in manufacturing as a pivotal component in broadening patient access to next-generation therapies, reaffirming the critical importance of initiatives like the new facility in Bristol.

Will Geist, President of Bio-Techne's Protein Sciences Segment, added, "The opening of our Bristol facility signifies more than just increased manufacturing capacity; it signifies our dedication to supporting cell therapy innovators by providing the quality, scalability, and global assistance essential for navigating the transition from concept to supply."

The Bristol facility is already operational, actively producing GMP-grade small molecules that support a diverse range of customers engaged in the development of innovative cell therapies across the globe.

About Bio-Techne

Founded in Minnesota nearly 50 years ago, Bio-Techne Corporation (NASDAQ: TECH) has emerged as a leading global entity in life sciences, serving scientific and diagnostic communities worldwide. With a diverse portfolio comprised of high-quality reagents, analytical instruments, and precision diagnostics, Bio-Techne operates in 34 locations globally and employs over 3,000 professionals. During the fiscal year 2025, the company reported an impressive $1.2 billion in net sales, highlighting its role as a trusted provider in the industry. Their commitment to quality is reflected in their extensive product range, utilized by academic researchers, biotechnology firms, and clinical diagnostic labs alike.

For further information about Bio-Techne and to explore its extensive offerings, visit Bio-Techne's official website or follow them on LinkedIn, X, or YouTube.